AstraZeneca Reports Higher Profits, But Cuts R&D Jobs

AstraZeneca's patent expiry woes clear amid disappointing '09 results.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet